Ipsen S.A. publie ses comptes consolidés 2024

February 21, 2025 09:42 ET | Source: Ipsen Pharma Ipsen Pharma

Ipsen S.A. - Etats financiers consolidés 2024

Pièce jointe

Ipsen_Comptes Consolidés 2024_FR

Attachments

Ipsen_Comptes Consolidés 2024_FR

Ipsen_Comptes Consolidés 2024_FR...

Recommended Reading

March 09, 2026 13:37 ET | Source: Ipsen Pharma

Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision...
Read More
March 09, 2026 02:00 ET | Source: Ipsen Pharma

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision...
Read More